Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.A group of researchers from institutes including the Mayo Clinic, Johns Hopkins Medicine and Wayne State University, has devised a new sustained-release drug delivery technology for retinal diseases.
Subscribe to our email newsletter
The system with dendrimers, is believed to deliver steroids into the targeted cells that cause neuroinflammation damage, which in turn leads to retinitis pigmentosa and can ultimately cause vision loss, azonano.com reported.
The research that was carried out in rats demonstrated a decrease in neuroinflammation development and their vision was protected as there was no damage to photoreceptors in the retina.
The study also suggested that though short-term protection is offered by steroids, as a whole the drug-delivery system will provide continuous protection against neuroinflammation.